Chief Operating Officer and Executive Vice President · Ultragenyx Pharmaceutical Inc. (RARE)

Wladimir Hogenhuis

FY2018 is the first fiscal year CompBrief holds for Wladimir Hogenhuis as a named executive officer of Ultragenyx Pharmaceutical; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2018

$5,257,804

Salary $110,923Stock awards $1,159,500Bonus $200,000

1st of 8 named executive officers at Ultragenyx Pharmaceutical by FY2018 total.

8 named officers on file for Ultragenyx Pharmaceutical, FY2018

Wladimir Hogenhuis’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 2 equity grants, each cited to its filing
  • RARE’s disclosed peer group of 19 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Ultragenyx Pharmaceutical’s whole pay program stands against its peers

  • Ultragenyx Pharmaceutical’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on RARE→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 22, 2019 (DEF 14A).

Free

Get Wladimir Hogenhuis’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Wladimir Hogenhuis compensation by year

Ultragenyx Pharmaceutical Summary Compensation Table · the one fiscal year held
In US dollars, as Ultragenyx Pharmaceutical reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2018
Salary$110,923
Bonus$200,000
Stock awards$1,159,500
Option awards$3,504,533
Non-equity incentive$67,021
Pension and deferred compensation$0
All other$215,827
Total$5,257,804

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Ultragenyx Pharmaceutical Inc. DEF 14A filed April 22, 2019, accession 0001193125-19-112719, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Ultragenyx Pharmaceutical Inc. filed document, accession 0001193125-19-112719. Every figure is read from that document and cited to the page and table it appears in. Filed April 22, 2019.

Equity holdings

unvested awards at FY2018 year-end
TypeUnvested unitsValue at year-endExercise price
RSU15,000$652,200—
Option75,000—$77.30

Per the Outstanding Equity Awards at Fiscal Year-End table in Ultragenyx Pharmaceutical Inc.'s FY2018 proxy; value at the fiscal year-end close, as the company printed it.

Ultragenyx Pharmaceutical’s named executive officers, FY2018

as the company reported each
Named executive officerRoleFY2018 total
Wladimir Hogenhuis · this pageChief Operating Officer and Executive Vice President$5,257,804
Camille BedrosianChief Medical Officer and Executive Vice President$4,846,292
Emil KakkisPresident and Chief Executive Officer$4,845,627
Shalini SharpChief Financial Officer and Executive Vice President$2,081,721
Karah ParschauerGeneral Counsel and Executive Vice President$2,036,330
Thomas KassbergChief Business Officer and Executive Vice President$1,692,660
John PinionChief Quality Officer and Executive Vice President, Translational Sciences$1,564,878
Erik HarrisChief Commercial Officer and Executive Vice President$641,070

The full Ultragenyx Pharmaceutical compensation record

free company brief

This page is one person within Ultragenyx Pharmaceutical's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Ultragenyx Pharmaceutical proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Ultragenyx Pharmaceutical's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Wladimir Hogenhuis's compensation dossier · One-time report. No refunds.